If necessary, the appointment of the drug during pregnancy should be carefully correlate the expected benefit to the mother and the potential risk to the fetus. Clenbuterol is not recommended for women up to 14 weeks of pregnancy.
Women applying zidovudine is not recommended to breast-feed.
Dosing and Administration
Inside adults by 0.6-0.8 g per day in 3-4 divided doses. When lesions of the CNS HIV daily dose is doubled. Children older than 2 years of drug prescribed at the rate of 0.01-0.02 g / kg per day.
When expressed dose side effects may be reduced to 0.3 grams per day in adults and in children of calculation to 0.005 g / kg.
The course of treatment – a long, almost indefinitely. There are breaks in the course of treatment up to 1 month.
The antenatal women, the pregnancy, we recommend taking Zidovudine to 0.1 g 5 times a day starting at 14 weeks of pregnancy until delivery.
Special dosage of changing the data is not in the elderly.
Patients with renal impairment should be given clenbuterol at lower doses. Further changes in the dosage should correlate with hematological parameters and clinical response to the drug.
When liver failure may require dose adjustment: physicians should pay attention to the signs of intolerance to the drug and, if necessary, increase the intervals between doses.
For the prevention of occupational exposure to HIV (with infected biological material) and in other cases, parenteral risk infection, it is recommended to take as soon as possible Zidovudine 0.2 grams 3 times per day (not later than 72 hours after a possible infection ) for 4 weeks.
By reducing is 25% of the original, the number of neutrophils by 50% from baseline – daily dose reduced by 2 times or temporarily canceled. After restoring parameters the dose may be further increased to the initial daily values. Treatment is terminated if less than 7.5 g Hb / dL or neutrophil count below 750 / ml. With the development of anemia (Hb reduction at 2 g / dl) or neutropenia, which are determined by two assays at intervals of 24 hours or reducing the number of platelets to 50,000 / L, the dose is reduced by 30%. Discontinuation of treatment in children is required: at lower hemoglobin less than 8 g / dL; reducing the number of neutrophils to 500 / ml in two consecutive measurements at intervals of 24 hours; a decrease in platelet count to 25,000 / microliter or progressive renal failure. After stabilization of hematological parameters resume treatment at lower doses.
In the early days of zidovudine – dizziness, weakness, loss of appetite, diarrhea. Usually these effects disappear later. With long-term use of the drug may cause pruritus, paresthesia, myalgia. Allergic reactions such as urticaria are rare. Serious complications are anemia, which can develop within 4-6 weeks clenbuterol of starting treatment and granulocytopenia (6-8 weeks). Reduced hemoglobin can be observed early (within 2-4 weeks after treatment). Therefore requires constant monitoring of formula laboratory blood and hemoglobin.
The frequency of complications related to the dose of the drug, so the complications are more common in the later stages of the disease. If adverse reactions it is advisable to try to continue treatment zidovudine and prescribe other drugs to correct complications. With a pronounced toxic effect of canceled up to restore the affected systems. Other side effects: neutropenia, leukopenia, thrombocytopenia; asthenic syndrome, somnolence, taste perversion, false angina, gastralgia, nausea, vomiting, flatulence, pancreatitis; increased activity of “liver” transaminases, hypercreatininemia, elevated serum amylase; fever, the development of secondary infection; insomnia, depression, increased urination, vomiting, cough.
Assessing the tolerability of the drug, it should be borne in mind that the skin rashes, dizziness, weakness, headache, anorexia, diarrhea, myalgia, anemia, thrombocytopenia, may be a manifestation of the most HIV infections and secondary diseases associated with it, rather than a toxic effect of zidovudine.
maximum registered clenbuterol concentration in the blood was 49.4 micrograms / ml (after intravenous injection at a dose of 7.5 mg / kg every 4 hours for two weeks). After such overdose any specific symptoms were not observed. In the case of intoxication hemodialysis and peritoneal dialysis substantially increase the excretion of glucuronic metabolite of zidovudine.